AUS
NZ
UK
CA
USA
IND
Highlights
- Imugene Limited (ASX:IMU) has onboarded industry and drug development expert Dr Jakob Dupont as its new Non-Executive Director.
- The new appointment will amplify the strength of the company as he brings with him immense industry, research, and academic experience.
- He is a known opinion leader for immune-oncology, cell therapy and early oncology drug development.
Immuno-oncology company, Imugene Limited (ASX:IMU) has appointed Dr Jakob Dupont as its new Non-Executive Director. On back of the announcement, shares of Imugene were spotted trading 3.4% higher at AU$0.227 each on ASX (on 7 September 2022 as at 12.26 PM AEST).
Dr Dupont, is a renowned industry and academic drug development expert, who holds expertise in oncology and other therapeutic areas. With over 20 years of experience, Dr Dupont has played a vital role and has contributed immensely to the development and approval of ten oncology drugs. For several drugs, he has been instrumental in successful development programs.
Dr Dupont’s extensive career profile
Presently, Dr Dupont is serving at NASDAQ-listed Atara Biotherapeutics (NASDAQ:ATRA) as the Global Head of Research and Development, looking after all research and development including three clinical stage programs spanning Phase 1 through to Phase 3, and other pre-clinical programs. He also takes care of important partnerships with academic as well as pharma players. Dr Dupont has been delivering leadership and guidance for multiple teams and plays the part of a spokesperson to the Board of Directors and investors.
In addition, Dr Dupont is also an Independent Director at Apexigen (NASDAQ:APGN) and a Scientific Advisory Board Member at AMBRX (NASDAQ:AMAM), currently.
Previously, he has worked at Genentech/Hoffman-La Roche for more than six years, where he was appointed at different roles, such as Global Head of Breast and GYN Cancer Development and Vice President. He was at Oncomed Pharmaceuticals as Senior Vice President and Chief Medical Officer, for around five years.
Interestingly, Dr Dupont has been published in peer-reviewed journals for more than 48 times. He holds strong relationships with collaborative groups, clinical and research oncologists, and investors globally.
Management Commentary
Image Source: ©2022 Kalkine Media®, Data Source: Company Announcement
Imugene achieved key milestones in June 2022 quarter, click here to know more.
